Ying Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ying Liu has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Jie Zhao
Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China
14 shared publications Yunfei Xu
Department of Neurology, Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, China
9 shared publicationsQing Xu
Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
8 shared publicationsShuying Miao
China-Africa Research Center of Infectious Diseases, Central South University, Changsha, China
8 shared publicationsYao Zhao
Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
7 shared publicationsJie Zhao
Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, People’s Republic of China
6 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by Springer Nature in Cellular and Molecular Neurobiology
Neurovascular Unit Dysfunction in Ischemic Stroke: Cellular and Molecular Mechanisms and Therapeutic Implications
- 15 September 2026
- Published by Springer Nature in Cellular and Molecular Neurobiology
Open AccessNeurovascular Unit Dysfunction in Ischemic Stroke: Cellular and Molecular Mechanisms and Therapeutic Implications
- Open Access
- 3 September 2025
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 21 (9) , 4076-4088
Prostaglandins: Key players in immunomodulation of the nervous system
As a class of bioactive substances that play important roles in a variety of physiological and pathological processes, prostaglandins have attracted increasing research attention. Published studies have identified the molecular characteristics of prostaglandins in peripheral organs, the enzymes involved in prostaglandin biosynthesis, and prostaglandin receptors. Some studies have also explored the characteristics of prostaglandins and their functions in the central nervous system. In particular, for immunomodulation, prostaglandins in the brain show a unique immunosuppressive effect, which is of great importance for maintaining brain immune homeostasis and preventing excessive immune responses. In this review, we review the biosynthesis and degradation of prostaglandins, discuss the regulatory effects of prostaglandin systems on the immune cells of the nervous system, and explore the therapeutic potential of targeting prostaglandin systems for neurological diseases, thereby providing new perspectives for the treatment of these diseases. Overall, prostaglandins play important roles in the immunomodulation of the nervous system, and the complexity of the underlying processes depends on the variety and types of specific receptors and, more importantly, the cell types prostaglandins act on. Therefore, additional in-depth studies of the specific mechanisms involving prostaglandins in immunomodulation, including the interactions among different types of prostaglandins and their roles in neuropathological conditions, are essential. The prostaglandin signaling pathway may represent another important direction for the development of new drugs for neurological diseases, and the combination of prostaglandin system targets with other therapies (such as immunomodulatory drugs and gene therapy) may yield better results.
- 3 September 2025
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 21 (9) , 4076-4088
Open AccessProstaglandins: Key players in immunomodulation of the nervous system
As a class of bioactive substances that play important roles in a variety of physiological and pathological processes, prostaglandins have attracted increasing research attention. Published studies have identified the molecular characteristics of prostaglandins in peripheral organs, the enzymes involved in prostaglandin biosynthesis, and prostaglandin receptors. Some studies have also explored the characteristics of prostaglandins and their functions in the central nervous system. In particular, for immunomodulation, prostaglandins in the brain show a unique immunosuppressive effect, which is of great importance for maintaining brain immune homeostasis and preventing excessive immune responses. In this review, we review the biosynthesis and degradation of prostaglandins, discuss the regulatory effects of prostaglandin systems on the immune cells of the nervous system, and explore the therapeutic potential of targeting prostaglandin systems for neurological diseases, thereby providing new perspectives for the treatment of these diseases. Overall, prostaglandins play important roles in the immunomodulation of the nervous system, and the complexity of the underlying processes depends on the variety and types of specific receptors and, more importantly, the cell types prostaglandins act on. Therefore, additional in-depth studies of the specific mechanisms involving prostaglandins in immunomodulation, including the interactions among different types of prostaglandins and their roles in neuropathological conditions, are essential. The prostaglandin signaling pathway may represent another important direction for the development of new drugs for neurological diseases, and the combination of prostaglandin system targets with other therapies (such as immunomodulatory drugs and gene therapy) may yield better results.
- 6 May 2025
- Published by Wolters Kluwer Health in Shock
- Vol. 64 (2) , 254-264
CO-CHAPERONE P23 INHIBITS FERROPTOSIS IN SEPSIS-ASSOCIATED ACUTE KIDNEY INJURY BY REGULATING GPX4 STABILITY
Ferroptosis, an iron-dependent form of regulated cell death, has been implicated in severe kidney diseases, particularly those characterized by the depletion of GPX4. Despite its clinical significance, the molecular mechanisms driving GPX4 reduction in SA-AKI remain poorly understood. In this study, we uncover a novel regulatory axis involving the RNA-binding protein P23 and GPX4 mRNA stability in SA-AKI pathogenesis. Using integrated in vivo and in vitro models, we demonstrate that P23 expression is significantly upregulated during SA-AKI and functions as a critical suppressor of ferroptosis. Mechanistically, pharmacological inhibition of P23 with celastrol exacerbated renal dysfunction and amplified ferroptotic damage, as evidenced by elevated lipid peroxidation, iron overload, and GPX4 downregulation. Conversely, P23 overexpression robustly attenuated ferroptosis by stabilizing GPX4 mRNA, thereby preserving GPX4 protein levels and redox homeostasis. Crucially, RIP and Co-immunoprecipitation assays revealed that P23 directly binds to GPX4 mRNA and protein, forming a protective complex that impedes mRNA degradation and ferroptotic cascades. These findings establish P23 as a multifunctional regulator of ferroptosis and highlight its RNA-binding activity as a therapeutically targetable mechanism for mitigating SA-AKI. Our work provides a foundation for developing P23-centric interventions to combat ferroptosis-driven kidney injury in sepsis.
- 6 May 2025
- Published by Wolters Kluwer Health in Shock
- Vol. 64 (2) , 254-264
CO-CHAPERONE P23 INHIBITS FERROPTOSIS IN SEPSIS-ASSOCIATED ACUTE KIDNEY INJURY BY REGULATING GPX4 STABILITY
Ferroptosis, an iron-dependent form of regulated cell death, has been implicated in severe kidney diseases, particularly those characterized by the depletion of GPX4. Despite its clinical significance, the molecular mechanisms driving GPX4 reduction in SA-AKI remain poorly understood. In this study, we uncover a novel regulatory axis involving the RNA-binding protein P23 and GPX4 mRNA stability in SA-AKI pathogenesis. Using integrated in vivo and in vitro models, we demonstrate that P23 expression is significantly upregulated during SA-AKI and functions as a critical suppressor of ferroptosis. Mechanistically, pharmacological inhibition of P23 with celastrol exacerbated renal dysfunction and amplified ferroptotic damage, as evidenced by elevated lipid peroxidation, iron overload, and GPX4 downregulation. Conversely, P23 overexpression robustly attenuated ferroptosis by stabilizing GPX4 mRNA, thereby preserving GPX4 protein levels and redox homeostasis. Crucially, RIP and Co-immunoprecipitation assays revealed that P23 directly binds to GPX4 mRNA and protein, forming a protective complex that impedes mRNA degradation and ferroptotic cascades. These findings establish P23 as a multifunctional regulator of ferroptosis and highlight its RNA-binding activity as a therapeutically targetable mechanism for mitigating SA-AKI. Our work provides a foundation for developing P23-centric interventions to combat ferroptosis-driven kidney injury in sepsis.
- Open Access
- 19 February 2025
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 55 (4) , 1-15
p23 protects against ferroptosis of brain microvascular endothelial cells in ischemic stroke
Ferroptosis is a type of iron‑dependent regulated cell death that differs from apoptosis, autophagy or necrosis. p23 serves as a co‑chaperone and performs a unique biological function in various diseases by binding to client proteins to modulate their biological functions; however, its effect on ferroptosis remains largely unknown. In the present study, the effects of cerebral ischemia/reperfusion (I/R) injury (CIRI) or oxygen‑glucose deprivation/reoxygenation on the blood‑brain barrier (BBB) and ferroptosis in brain microvascular endothelial cells (BMECs), as well as the expression of p23, were examined. Subsequently, the effects of p23 on CIRI‑induced BBB dysfunction and BMEC ferroptosis were determined. Finally, the role of glutathione peroxidase 4 (GPX4) in the regulatory effects of p23 on ferroptosis was detected. The results revealed that p23 protected against BBB injury caused by CIRI by inhibiting ferroptosis in BMECs. The effect of p23 on ferroptosis was then explored, and it was found that the expression of GPX4, a major regulator of ferroptosis, was promoted by p23. Furthermore, molecular docking and co‑immunoprecipitation experiments revealed that p23 could bind to GPX4 through its N‑terminal domain (1‑90aa), enhance the stability of GPX4 and inhibit the degradation of GPX4 by cycloheximide. Finally, a cerebral I/R animal model was established using GPX4 conditional knockout mice (GPX4 FosCreERT2/+), and it was revealed that the protective effect of p23 overexpression on the BBB in GPX4 FosCreERT2/+ mice was attenuated compared with that in GPX4 FosCreERT2/‑ mice. In conclusion, p23 may serve a protective role against cerebral I/R‑induced BBB injury by inhibiting ferroptosis in BMECs through enhancing the stability of GPX4, providing a potential therapeutic target for ischemic stroke.
- 19 February 2025
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 55 (4) , 1-15
Open Accessp23 protects against ferroptosis of brain microvascular endothelial cells in ischemic stroke
Ferroptosis is a type of iron‑dependent regulated cell death that differs from apoptosis, autophagy or necrosis. p23 serves as a co‑chaperone and performs a unique biological function in various diseases by binding to client proteins to modulate their biological functions; however, its effect on ferroptosis remains largely unknown. In the present study, the effects of cerebral ischemia/reperfusion (I/R) injury (CIRI) or oxygen‑glucose deprivation/reoxygenation on the blood‑brain barrier (BBB) and ferroptosis in brain microvascular endothelial cells (BMECs), as well as the expression of p23, were examined. Subsequently, the effects of p23 on CIRI‑induced BBB dysfunction and BMEC ferroptosis were determined. Finally, the role of glutathione peroxidase 4 (GPX4) in the regulatory effects of p23 on ferroptosis was detected. The results revealed that p23 protected against BBB injury caused by CIRI by inhibiting ferroptosis in BMECs. The effect of p23 on ferroptosis was then explored, and it was found that the expression of GPX4, a major regulator of ferroptosis, was promoted by p23. Furthermore, molecular docking and co‑immunoprecipitation experiments revealed that p23 could bind to GPX4 through its N‑terminal domain (1‑90aa), enhance the stability of GPX4 and inhibit the degradation of GPX4 by cycloheximide. Finally, a cerebral I/R animal model was established using GPX4 conditional knockout mice (GPX4 FosCreERT2/+), and it was revealed that the protective effect of p23 overexpression on the BBB in GPX4 FosCreERT2/+ mice was attenuated compared with that in GPX4 FosCreERT2/‑ mice. In conclusion, p23 may serve a protective role against cerebral I/R‑induced BBB injury by inhibiting ferroptosis in BMECs through enhancing the stability of GPX4, providing a potential therapeutic target for ischemic stroke.
- 17 December 2024
- Published by Wolters Kluwer Health in Shock
- Vol. 63 (4) , 628-637
GASTRODIN PROTECTS AGAINST SEPSIS-ASSOCIATED ENCEPHALOPATHY BY SUPPRESSING FERROPTOSIS
Background: Sepsis-associated encephalopathy (SAE) represents a severe complication of sepsis, substantially elevating both mortality and healthcare costs for patients. Gastrodin (GAS), a principal bioactive constituent of Gastrodia elata Blume, is neuroprotective in various neurological disorders, including ischemic stroke, epilepsy, Alzheimer’s disease, and neuropathic pain. In this study, we sought to investigate whether GAS could serve as a protective agent against SAE. Methods: Mice were subjected to cecal ligation and puncture (CLP) or the murine brain microvascular endothelial cell bEnd.3 was exposed to lipopolysaccharide (LPS) and subsequently treated with GAS. We assessed neurological deficits, blood-brain barrier (BBB) integrity, neuroinflammation, and the state of ferroptosis to evaluate the regulation of GAS on SAE. Mechanistically, we utilized glutathione peroxidase 4 (GPX4) knockout mice to delineate the crucial role of GPX4 and examined the cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2) pathway to uncover the upstream signaling of GPX4. Results: GAS mitigated neurological deficits in SAE mice and reduced BBB disruption and neuroinflammation both in vivo and in vitro. Functionally, the neuroprotective effects of GAS were realized through the inhibition of ferroptosis. Furthermore, we demonstrated that GPX4 played a pivotal role in this process. Lastly, we found that the COX-2/PGE2 pathway was activated following GAS treatment in SAE mice, thereby increasing the expression level of GPX4. Conclusions: Our study elucidated that GAS offers protection against SAE by suppressing ferroptosis through the activation of the COX-2/PGE2/GPX4 axis. This research validates the therapeutic potential of GAS and provides novel insights into potential therapeutic strategies for the management of SAE.
- 17 December 2024
- Published by Wolters Kluwer Health in Shock
- Vol. 63 (4) , 628-637
GASTRODIN PROTECTS AGAINST SEPSIS-ASSOCIATED ENCEPHALOPATHY BY SUPPRESSING FERROPTOSIS
Background: Sepsis-associated encephalopathy (SAE) represents a severe complication of sepsis, substantially elevating both mortality and healthcare costs for patients. Gastrodin (GAS), a principal bioactive constituent of Gastrodia elata Blume, is neuroprotective in various neurological disorders, including ischemic stroke, epilepsy, Alzheimer’s disease, and neuropathic pain. In this study, we sought to investigate whether GAS could serve as a protective agent against SAE. Methods: Mice were subjected to cecal ligation and puncture (CLP) or the murine brain microvascular endothelial cell bEnd.3 was exposed to lipopolysaccharide (LPS) and subsequently treated with GAS. We assessed neurological deficits, blood-brain barrier (BBB) integrity, neuroinflammation, and the state of ferroptosis to evaluate the regulation of GAS on SAE. Mechanistically, we utilized glutathione peroxidase 4 (GPX4) knockout mice to delineate the crucial role of GPX4 and examined the cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2) pathway to uncover the upstream signaling of GPX4. Results: GAS mitigated neurological deficits in SAE mice and reduced BBB disruption and neuroinflammation both in vivo and in vitro. Functionally, the neuroprotective effects of GAS were realized through the inhibition of ferroptosis. Furthermore, we demonstrated that GPX4 played a pivotal role in this process. Lastly, we found that the COX-2/PGE2 pathway was activated following GAS treatment in SAE mice, thereby increasing the expression level of GPX4. Conclusions: Our study elucidated that GAS offers protection against SAE by suppressing ferroptosis through the activation of the COX-2/PGE2/GPX4 axis. This research validates the therapeutic potential of GAS and provides novel insights into potential therapeutic strategies for the management of SAE.
- 19 November 2024
- Published by Springer Nature in Frontiers of Medicine
- Vol. 19 (1) , 1-22
Ferroptosis contributes to immunosuppression
As a novel form of cell death, ferroptosis is mainly regulated by the accumulation of soluble iron ions in the cytoplasm and the production of lipid peroxides and is closely associated with several diseases, including acute kidney injury, ischemic reperfusion injury, neurodegenerative diseases, and cancer. The term “immunosuppression” refers to various factors that can directly harm immune cells’ structure and function and affect the synthesis, release, and biological activity of immune molecules, leading to the insufficient response of the immune system to antigen production, failure to successfully resist the invasion of foreign pathogens, and even organ damage and metabolic disorders. An immunosuppressive phase commonly occurs in the progression of many ferroptosis-related diseases, and ferroptosis can directly inhibit immune cell function. However, the relationship between ferroptosis and immunosuppression has not yet been published due to their complicated interactions in various diseases. Therefore, this review deeply discusses the contribution of ferroptosis to immunosuppression in specific cases. In addition to offering new therapeutic targets for ferroptosis-related diseases, the findings will help clarify the issues on how ferroptosis contributes to immunosuppression.
- 19 November 2024
- Published by Springer Nature in Frontiers of Medicine
- Vol. 19 (1) , 1-22
Ferroptosis contributes to immunosuppression
As a novel form of cell death, ferroptosis is mainly regulated by the accumulation of soluble iron ions in the cytoplasm and the production of lipid peroxides and is closely associated with several diseases, including acute kidney injury, ischemic reperfusion injury, neurodegenerative diseases, and cancer. The term “immunosuppression” refers to various factors that can directly harm immune cells’ structure and function and affect the synthesis, release, and biological activity of immune molecules, leading to the insufficient response of the immune system to antigen production, failure to successfully resist the invasion of foreign pathogens, and even organ damage and metabolic disorders. An immunosuppressive phase commonly occurs in the progression of many ferroptosis-related diseases, and ferroptosis can directly inhibit immune cell function. However, the relationship between ferroptosis and immunosuppression has not yet been published due to their complicated interactions in various diseases. Therefore, this review deeply discusses the contribution of ferroptosis to immunosuppression in specific cases. In addition to offering new therapeutic targets for ferroptosis-related diseases, the findings will help clarify the issues on how ferroptosis contributes to immunosuppression.
- 22 June 2024
- Published by Elsevier in Clinical Immunology
- Vol. 265, 110298
Roles of prostaglandins in immunosuppression
- 22 June 2024
- Published by Elsevier in Clinical Immunology
- Vol. 265, 110298
Roles of prostaglandins in immunosuppression
- Open Access
- 12 May 2023
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 18 (12) , 2638-2644
Molecular chaperones in stroke-induced immunosuppression
Stroke-induced immunosuppression is a process that leads to peripheral suppression of the immune system after a stroke and belongs to the central nervous system injury-induced immunosuppressive syndrome. Stroke-induced immunosuppression leads to increased susceptibility to post-stroke infections, such as urinary tract infections and stroke-associated pneumonia, worsening prognosis. Molecular chaperones are a large class of proteins that are able to maintain proteostasis by directing the folding of nascent polypeptide chains, refolding misfolded proteins, and targeting misfolded proteins for degradation. Various molecular chaperones have been shown to play roles in stroke-induced immunosuppression by modulating the activity of other molecular chaperones, cochaperones, and their associated pathways. This review summarizes the role of molecular chaperones in stroke-induced immunosuppression and discusses new approaches to restore host immune defense after stroke.
- 12 May 2023
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 18 (12) , 2638-2644
Open AccessMolecular chaperones in stroke-induced immunosuppression
Stroke-induced immunosuppression is a process that leads to peripheral suppression of the immune system after a stroke and belongs to the central nervous system injury-induced immunosuppressive syndrome. Stroke-induced immunosuppression leads to increased susceptibility to post-stroke infections, such as urinary tract infections and stroke-associated pneumonia, worsening prognosis. Molecular chaperones are a large class of proteins that are able to maintain proteostasis by directing the folding of nascent polypeptide chains, refolding misfolded proteins, and targeting misfolded proteins for degradation. Various molecular chaperones have been shown to play roles in stroke-induced immunosuppression by modulating the activity of other molecular chaperones, cochaperones, and their associated pathways. This review summarizes the role of molecular chaperones in stroke-induced immunosuppression and discusses new approaches to restore host immune defense after stroke.
- 1 May 2023
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 324 (5) , C1039-C1052
Cancer-associated fibroblasts suppressed ferroptosis in glioblastoma via upregulating lncRNA DLEU1
Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults. It is crucial to elucidate the mechanism underlying ferroptosis resistance in GBM. We used qRT-PCR to detect the level of DLEU1 and mRNAs of indicated genes, whereas protein levels were determined by Western blots. Fluorescence in situ hybridization assay (FISH) was applied to validate the sublocation of DLEU1 in GBM cells. Gene knockdown or overexpression was achieved by transient transfection. Ferroptosis markers were detected by indicated kits and transmission electron microscopy (TEM). RNA pull-down, RNA immunoprecipitation (RIP), chromatin immunoprecipitation (CHIP)-qPCR, and dual-luciferase assay were used to validate the direct interaction between indicated key molecules in the current study. We validated that the expression of DLEU1 was upregulated in GBM samples. DLEU1 knockdown exacerbated erastin-induced ferroptosis in LN229 and U251MG cells, as well as in the xenograft model. Mechanistically, we found that DLEU1 bound with ZFP36 and facilitated ZFP36 to degrade ATF3 mRNA, thus upregulating the expression of SLC7A11 to attenuate erastin-induced ferroptosis. Importantly, our results confirmed that cancer-associated fibroblasts (CAFs) conferred ferroptosis resistance in GBM. The stimulation of CAF-conditioned medium enhanced the activation of HSF1, and HSF1 transcriptionally increased the level of DLEU1 to regulate erastin-induced ferroptosis. This study identified DLEU1 as an oncogenic lncRNA that epigenetically downregulates ATF3 expression via binding with ZFP36 to facilitate ferroptosis resistance in GBM. The upregulation of DLEU1 in GBM might be attributed to CAF-induced HSF1 activation. Our study might provide a research basis for understanding CAF-induced ferroptosis resistance in GBM.
- 1 May 2023
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 324 (5) , C1039-C1052
Cancer-associated fibroblasts suppressed ferroptosis in glioblastoma via upregulating lncRNA DLEU1
Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults. It is crucial to elucidate the mechanism underlying ferroptosis resistance in GBM. We used qRT-PCR to detect the level of DLEU1 and mRNAs of indicated genes, whereas protein levels were determined by Western blots. Fluorescence in situ hybridization assay (FISH) was applied to validate the sublocation of DLEU1 in GBM cells. Gene knockdown or overexpression was achieved by transient transfection. Ferroptosis markers were detected by indicated kits and transmission electron microscopy (TEM). RNA pull-down, RNA immunoprecipitation (RIP), chromatin immunoprecipitation (CHIP)-qPCR, and dual-luciferase assay were used to validate the direct interaction between indicated key molecules in the current study. We validated that the expression of DLEU1 was upregulated in GBM samples. DLEU1 knockdown exacerbated erastin-induced ferroptosis in LN229 and U251MG cells, as well as in the xenograft model. Mechanistically, we found that DLEU1 bound with ZFP36 and facilitated ZFP36 to degrade ATF3 mRNA, thus upregulating the expression of SLC7A11 to attenuate erastin-induced ferroptosis. Importantly, our results confirmed that cancer-associated fibroblasts (CAFs) conferred ferroptosis resistance in GBM. The stimulation of CAF-conditioned medium enhanced the activation of HSF1, and HSF1 transcriptionally increased the level of DLEU1 to regulate erastin-induced ferroptosis. This study identified DLEU1 as an oncogenic lncRNA that epigenetically downregulates ATF3 expression via binding with ZFP36 to facilitate ferroptosis resistance in GBM. The upregulation of DLEU1 in GBM might be attributed to CAF-induced HSF1 activation. Our study might provide a research basis for understanding CAF-induced ferroptosis resistance in GBM.
- Open Access
- 3 March 2023
- Published by Springer Nature in Research Square
Validation of TBL-PBL Teaching Model in the Organ System-based Medical Curriculum
BACKGROUND The organ system-based medical curriculum is crucial for students in the MD-PhD program of Xiangya School of Medicine at Central South University in China. The combination of Team Based Learning (TBL) and Problem Based Learning (PBL) forms a new case-based teaching model so that students can cooperatively participate in case discussions using multi-disciplinary knowledge. The aim of this study is to utilize TBL-PBL teaching model in the organ system-based medical curriculum, and assess the feedback on teaching arrangement, effectiveness and the academic performance of students. METHODS This is a single institution, two-year study that includes two cohorts of students who participated in two training paradigms, traditional teaching model and TBL-PBL teaching modal. The MD-PhD students enrolled in 2016 (n=100) were selected for traditional teaching model, students enrolled in 2017 (n=100) were selected for TBL-PBL teaching model, in which the learning contents were remodeled and integrated with simulated cases, taught by an interprofessional team. After completing the curriculmn, all students were surveyed on their feedbacks about group teaching arrangement and teaching effectiveness. Academic performance were also assesses by post-session quizzes, periodical tests and the final exams. RESULTS The survey results revealed that in the TBL-PBL teaching group, the percentage of students who thought that the teaching objectives were challenging reached 94%. Meanwhile, for the traditional teaching group, the percentage of students who thought likewise were 84%. The percentage of students in the TBL-PBL group who thought that the innovative teaching mode rendered helpful in consolidating basic medical knowledge structure (89% vs. 78%), promoted student overall thinking skills (94% vs. 84%), communication skills(93% vs. 82%), teamwork skills (95% vs. 82%) and professional abilities (89% vs. 84%) outweighed the traditional teaching group to a significant degree. The academic performance in the TBL-PBL group was improved evidenced by higher class scores(85.52 vs. 80.34), excellence rate (51% vs. 49%) and qualification rate (100% vs. 92%). CONCLUSION The TBL-PBL teaching model improved academic performance, yielded higher student satisfaction and engagement. This innovative teaching model can be used as an alternative to traditional model for medical courses.
- 3 March 2023
- Published by Springer Nature in Research Square
Open AccessValidation of TBL-PBL Teaching Model in the Organ System-based Medical Curriculum
BACKGROUND The organ system-based medical curriculum is crucial for students in the MD-PhD program of Xiangya School of Medicine at Central South University in China. The combination of Team Based Learning (TBL) and Problem Based Learning (PBL) forms a new case-based teaching model so that students can cooperatively participate in case discussions using multi-disciplinary knowledge. The aim of this study is to utilize TBL-PBL teaching model in the organ system-based medical curriculum, and assess the feedback on teaching arrangement, effectiveness and the academic performance of students. METHODS This is a single institution, two-year study that includes two cohorts of students who participated in two training paradigms, traditional teaching model and TBL-PBL teaching modal. The MD-PhD students enrolled in 2016 (n=100) were selected for traditional teaching model, students enrolled in 2017 (n=100) were selected for TBL-PBL teaching model, in which the learning contents were remodeled and integrated with simulated cases, taught by an interprofessional team. After completing the curriculmn, all students were surveyed on their feedbacks about group teaching arrangement and teaching effectiveness. Academic performance were also assesses by post-session quizzes, periodical tests and the final exams. RESULTS The survey results revealed that in the TBL-PBL teaching group, the percentage of students who thought that the teaching objectives were challenging reached 94%. Meanwhile, for the traditional teaching group, the percentage of students who thought likewise were 84%. The percentage of students in the TBL-PBL group who thought that the innovative teaching mode rendered helpful in consolidating basic medical knowledge structure (89% vs. 78%), promoted student overall thinking skills (94% vs. 84%), communication skills(93% vs. 82%), teamwork skills (95% vs. 82%) and professional abilities (89% vs. 84%) outweighed the traditional teaching group to a significant degree. The academic performance in the TBL-PBL group was improved evidenced by higher class scores(85.52 vs. 80.34), excellence rate (51% vs. 49%) and qualification rate (100% vs. 92%). CONCLUSION The TBL-PBL teaching model improved academic performance, yielded higher student satisfaction and engagement. This innovative teaching model can be used as an alternative to traditional model for medical courses.